Avenue Therapeutics shareholders elect directors, ratify KPMG auditor

Avenue Therapeutics ( (ATXI) ) has provided an update.

At its 2025 annual meeting of stockholders held virtually on December 30, 2025, Avenue Therapeutics, Inc. shareholders elected six directors — including Jay Kranzler, Faith Charles, Neil Herskowitz, Alexandra MacLean, Curtis Oltmans and Lindsay A. Rosenwald — to serve until the 2026 annual meeting, with each nominee receiving strong majority support. Investors also ratified the appointment of KPMG LLP as Avenue’s independent registered public accounting firm for the fiscal year ending December 31, 2025, reinforcing continuity in the company’s governance and audit oversight, with all 3,183,426 outstanding common shares and 250,000 Class A preferred shares eligible to vote under the company’s capital structure.

The most recent analyst rating on (ATXI) stock is a Hold with a $0.64 price target. To see the full list of analyst forecasts on Avenue Therapeutics stock, see the ATXI Stock Forecast page.

Spark’s Take on ATXI Stock

According to Spark, TipRanks’ AI Analyst, ATXI is a Neutral.

The score is primarily constrained by ongoing operating losses and negative free cash flow despite improving trends and a debt-free balance sheet. Technical indicators also lean bearish with weak momentum. Offsetting these risks, the Baergic sale to Axsome is a notable positive that may improve flexibility, but profitability and sustained cash generation remain key gaps.

To see Spark’s full report on ATXI stock, click here.

More about Avenue Therapeutics

Avenue Therapeutics, Inc. is a specialty pharmaceutical company in the biopharmaceutical industry focused on developing and commercializing therapeutics, with its capital structure including both common stock and Class A preferred stock with enhanced voting rights.

Average Trading Volume: 2,718

Technical Sentiment Signal: Sell

Current Market Cap: $2.07M

For an in-depth examination of ATXI stock, go to TipRanks’ Overview page.